Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Alopecia totalis/universalis involves more intense immune activity and inflammation than patchy alopecia areata.

This study found that among adults with severe alopecia areata, alopecia totalis, or alopecia universalis, oral tofacitinib was more effective than methotrexate in reducing hair loss over a 12-week period, though long-term safety and efficacy remain unestablished.

In this reported case, a 30-year-old man with a long history of alopecia universalis experienced limited regrowth of eyebrows and eyelashes after six months of deuruxolitinib, despite unchanged scalp hair, suggesting site-specific potential for hair regrowth in challenging cases.

Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.

In this case report, the researchers observed that a woman with longstanding Alopecia Universalis, who had not responded to various treatments, experienced hair regrowth and improved quality of life after two years of individualized homeopathic treatment centered around Natrum Muriaticum.

In this case report, a 25-year-old male with alopecia universalis showed sustained hair regrowth and psychological improvements over 21 months following individualized homeopathic treatment, despite prior failures with conventional therapies, as observed at Dr Batra’s® Homeopathy Clinic.

In this case report, a 30-year-old woman with myasthenia gravis developed vitiligo and alopecia universalis during long-term rituximab therapy. Discontinuation of rituximab and initiation of oral baricitinib led to improvement in skin conditions, underscoring potential immune-related skin effects from rituximab.

In this case report, a 30-year-old woman with myasthenia gravis developed vitiligo and alopecia universalis during long-term rituximab therapy, suggesting a rare association between the drug and these immune-mediated skin conditions, highlighting the potential benefit of early intervention with baricitinib.

In this study, a patient with over 40 years of Alopecia Universalis achieved complete regrowth of hair on the scalp and eyebrows within less than three years after consistent treatment with oral Tofacitinib, suggesting its potential as a promising therapy for this condition.

This report describes a case of severe hair loss with accompanying thyroid issues and eczema that improved noticeably after individualized homeopathic treatment, following unsuccessful previous methods, as observed at Dr Batra’s® Homeopathy Clinic.

This study observed that patients using dupilumab for atopic dermatitis or chronic rhinosinusitis with nasal polyps may experience new-onset or worsening paradoxical alopecia areata, potentially due to unopposed Th1/Th17 immune activity following Th2 pathway blockade.

In this case report, a 26-year-old man with alopecia universalis, resistant to multiple standard treatments, achieved complete and sustained hair regrowth with ruxolitinib, highlighting its potential as a promising option for patients with refractory AU.

This case report presents the first instance of a pediatric alopecia areata patient switching from baricitinib to ritlecitinib, demonstrating favorable clinical outcomes, suggesting a potential new treatment pathway for children with severe cases of this condition.

This study observed that JAK inhibitors were effective and safe for treating alopecia totalis and universalis, with improved response rates seen most with ritlecitinib and tofacitinib by week 24.

In this case study, a 5-year-old girl with alopecia areata and atopic dermatitis that were unresponsive to previous treatments achieved substantial improvement with long-term tofacitinib, highlighting its potential safety and efficacy in managing both conditions concurrently.

This study assessed oral tofacitinib's effectiveness and safety in treating different forms of alopecia, finding that 80% of patients experienced hair regrowth improvements over 24 weeks with no adverse events reported.

In this study, among 2,000 patients with alopecia universalis, mesotherapy combined with systemic treatments like BMI, JAK inhibitors, and adalimumab showed the highest success in hair regrowth, particularly for children, with the combination therapy group achieving a 42% positive response rate.

This case report describes a 79-year-old woman who developed alopecia universalis shortly after recovering from COVID-19, highlighting its relapsing nature and the challenges in long-term disease management.

This study found that topical immunotherapy is effective for treating severe alopecia areata, though patient responses can vary, highlighting the importance of individualized treatment approaches and prolonged therapy to optimize outcomes.

This study reports that a combination of upadacitinib and oral minoxidil resulted in complete hair regrowth in a 20-year-old with alopecia universalis, Crohn's disease, and atopic dermatitis.

This case study reported significant hair regrowth and overall improvement in well-being for a male with Alopecia Universalis after receiving classical homeopathic treatment at Dr. Batra’s, suggesting potential long-term benefits from this intervention.

This case report describes a five-year-old boy with Alopecia Universalis who did not respond to allopathic treatments but showed significant hair regrowth after two months of Ayurveda therapies, suggesting their potential effectiveness for this condition.

This case study reported on a 30-year-old male with autoimmune polyglandular syndrome type 2, highlighting rare co-occurrence with alopecia universalis and emphasizing the importance of recognizing non-endocrine symptoms for early diagnosis and management of autoimmune endocrinopathies.

This case study reports significant improvements in joint pain and hair regrowth in a 31-year-old female with alopecia universalis, psoriasis vulgaris, and psoriatic arthritis using a combination of tofacitinib and methotrexate after other treatments failed.

In this case study, a nine-year-old boy with alopecia universalis following severe chickenpox showed complete hair regrowth after treatment with tofacitinib, suggesting the drug's potential in managing varicella-zoster virus-induced alopecia by modulating immune responses.

This study concluded that oral tofacitinib significantly improved hair growth in patients with alopecia areata, alopecia totalis, and alopecia universalis over a 24-week period, but longer studies are needed to assess long-term safety.

This abstract does not report any research results but mentions researcher affiliations and potential conflicts of interest, indicating the researchers' involvement in various pharmaceutical collaborations.

In this study, tofacitinib showed significant efficacy in treating alopecia totalis and universalis over a 6-month period, with notable hair regrowth outcomes, while younger age of onset and shorter treatment duration were linked to less effectiveness.

This study reports a case where a patient with both psoriasis and alopecia universalis experienced regrowth of scalp and body hair after treatment with Deucravacitinib, a TYK2 inhibitor, suggesting potential effectiveness but recommending controlled studies to confirm this finding.

This case report observed successful hair regrowth with ritlecitinib in a patient with severe alopecia who did not respond to a previous year of baricitinib therapy.